Navigation Links
Infinata’s BioPharm Insight Gears Up for the 2013 American College of Cardiology Meeting with the Release of its Cardiovascular Diseases Report
Date:3/7/2013

is apt to require CV outcomes results for Merck’s other combination drug, Zetia/atorvastatin prior to approval.

While enthusiasm for the cholesteryl ester transfer protein (CETP) inhibitor class dwindles after the HPS2-THRIVE trial failed to meet its endpoint, anti-PCSK9 strategies such as those by Regeneron Pharmaceuticals, Sanofi and Amgen have garnered a great deal of enthusiasm. This past November, BioPharm Insight reported that Regeneron/Sanofi's SAR236553/REGN727 and Amgen's AMG 145 were likely to yield similarly efficacious cholesterol-lowering effects in Phase III assessment.

Additional report highlights include:

  •     AMG 145, an anti-PCK9, proves an unlikely fit for homozygous familial hypercholesterolemia (hoFH).
  •     Aegerion faces uncertainty in its quest for EU approval of Juxtapid.
  •     GlaxoSmithKline's atherosclerosis candidate darapladib faces low prospects of demonstrating significant CV event reduction.

Access all of BioPharm Insight’s reports by starting a free trial today.

About BioPharm Insight
BioPharm Insight is the definitive guide to the global biopharma community. BioPharm Insight provides subscribers with an information edge by combining the most comprehensive real-time database of companies, drugs, contacts, M&A and licensing deals, forecasts and clinical trial data with proprietary forward-looking intelligence uncovered by an independent team of investigative journalists months or even years before it breaks in mainstream media. To learn more, visit ht
'/>"/>

Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Infinata’s BioPharm Insight™ Achieves Record Growth in 2012
2. Infinata’s BioPharm Insight Signs 200th Media Partner, Inaugurates Advertising Program
3. Infinata’s BioPharm Insight Releases Licensing League Tables Report for 4Q12 and YE12
4. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentations of Zerenex™ (Ferric Citrate) at the Upcoming American Society of Nephrology Kidney Week 2011 Annual Meeting
5. PDL BioPharma Announces Adjusted Conversion Rates for Its Convertible Notes
6. CeNeRx BioPharma Completes $4.85 Million Financing
7. PDL BioPharma Completes Regular Quarterly Dividend Payment
8. PAREXEL Introduces Executive Briefing Series on Proven Practices to Assist Emerging and Mid-size Biopharma in Achieving Better Outcomes
9. Inspiration Biopharmaceuticals Moves Corporate Headquarters to Cambridge, Massachusetts
10. Keryx Biopharmaceuticals to Present at JP Morgans 30th Annual Healthcare Conference
11. HealthCare Institute of New Jersey Releases 2011 Biopharmaceutical and Medical Technology Economic Impact Data
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/31/2015)... DUBLIN , Aug. 31, 2015 Research ... of the "Middle East & Africa Biomedical Sensors ... to their offering. The ... is estimated at $0.84 billion by 2018 at a ... The near future will bring Biomedical sensors that are ...
(Date:8/31/2015)... 2015  RXi Pharmaceuticals Corporation (NASDAQ: RXII ... developing innovative therapies primarily in the areas of ... review period following the filing of the Company,s ... the U.S. Food and Drug Administration (FDA) has ... Logo -  http://photos.prnewswire.com/prnh/20130917/NE80755LOGO ...
(Date:8/31/2015)... , Aug. 31, 2015 FLX Bio, Inc., ... of novel cancer immunotherapies, announced today that it has ... Executive Officer and William Ho , M.D., Ph.D., ... an experienced management team led by veterans of Flexus ... Ph.D., Chief Scientific Officer; Jay Powers , Ph.D., ...
(Date:8/31/2015)... ... August 31, 2015 , ... Regulatory ... in the drug development approval process. Thus, innovator companies must understand what will ... Inc., a Chicago-based CMO, has been hosting multiple educational panels and seminars for ...
Breaking Biology Technology:Middle East & Africa Biomedical Sensors Market Report 2015 - Growth, Trends & Forecasts to 2020 2RXi Pharmaceuticals Announces Advancements in its Ophthalmology Clinical Program with RXI-109 2RXi Pharmaceuticals Announces Advancements in its Ophthalmology Clinical Program with RXI-109 3RXi Pharmaceuticals Announces Advancements in its Ophthalmology Clinical Program with RXI-109 4FLX Bio Announces Senior Management Hires and Initiation of Phase 1 Trial of FLX925 2FLX Bio Announces Senior Management Hires and Initiation of Phase 1 Trial of FLX925 3FLX Bio Announces Senior Management Hires and Initiation of Phase 1 Trial of FLX925 4Regis Shares Expert Advice on Impurities in Drug Development 2Regis Shares Expert Advice on Impurities in Drug Development 3
... , SAN DIEGO, Calif., INDIANAPOLIS, Ind., and CAMBRIDGE, ... ), Eli Lilly and Company (NYSE: LLY ) and Alkermes, ... 20 studies at the 45th Annual Meeting of the European Association for ... 29 to Oct. 2. The companies will present the latest research findings ...
... ... million round of funding. Participating investors included CTTV Investments LLC, the venture capital ... , ... Francisco, CA (PRWEB) September 24, 2009 -- LS9, Inc., the Renewable Petroleum Company™, today ...
... , , PHILADELPHIA and LONDON, ... -- researchers likely to be in contention for Nobel honors -- in anticipation ... be announced from October 5-12. , , Thomson Reuters ... Nobel Prize winners. , , Each year, data ...
Cached Biology Technology:Amylin and Lilly to Present More than 20 Studies for Exenatide at EASD 2009 2Amylin and Lilly to Present More than 20 Studies for Exenatide at EASD 2009 3Amylin and Lilly to Present More than 20 Studies for Exenatide at EASD 2009 4Amylin and Lilly to Present More than 20 Studies for Exenatide at EASD 2009 5Amylin and Lilly to Present More than 20 Studies for Exenatide at EASD 2009 6Amylin and Lilly to Present More than 20 Studies for Exenatide at EASD 2009 7LS9 Secures $25 Million in Latest Round of Funding 2LS9 Secures $25 Million in Latest Round of Funding 3Thomson Reuters Predicts Nobel Laureates 2Thomson Reuters Predicts Nobel Laureates 3Thomson Reuters Predicts Nobel Laureates 4Thomson Reuters Predicts Nobel Laureates 5Thomson Reuters Predicts Nobel Laureates 6
(Date:8/17/2015)... Aug. 17, 2015  NXT-ID, Inc. (NASDAQ: NXTD ... focused on the growing mobile commerce market and creator ... campaign for Q4 2015. The new marketing campaign is ... of Amplitude Marketing Group ( http://amplitudemarketing.com/ ) and TPMG ... a leader in retail driven marketing and brand awareness ...
(Date:8/12/2015)... , August 12, 2015 ... of mobile payment innovation and advanced biometrics technology is ... the way consumers rely on using their credit cards, ... reinventing the future for payment services led by companies ... NXTD ), :  Google, Inc. (NASDAQ: GOOG ), ...
(Date:8/12/2015)... , Aug. 12, 2015  Synaptics Inc. (NASDAQ: ... interface solutions, today announced that four of its ... solution, have officially been named FIDO Certified™ by ... of the certification, Synaptics, Natural ID™ fingerprint solutions ... Authentication Framework (UAF) standard and are interoperable among ...
Breaking Biology News(10 mins):NXT-ID, Inc. Launches Sales Campaign for Wocket Smart Wallet with Award Winning Marketing Team 2NXT-ID, Inc. Launches Sales Campaign for Wocket Smart Wallet with Award Winning Marketing Team 3Digital Wallet Devices & Mobile Payment Management Services Gain a Distinct Advantage in the Digital Payment Evolution as Demand Continues to Grow 2Digital Wallet Devices & Mobile Payment Management Services Gain a Distinct Advantage in the Digital Payment Evolution as Demand Continues to Grow 3Digital Wallet Devices & Mobile Payment Management Services Gain a Distinct Advantage in the Digital Payment Evolution as Demand Continues to Grow 4Digital Wallet Devices & Mobile Payment Management Services Gain a Distinct Advantage in the Digital Payment Evolution as Demand Continues to Grow 5Digital Wallet Devices & Mobile Payment Management Services Gain a Distinct Advantage in the Digital Payment Evolution as Demand Continues to Grow 6Synaptics Announces FIDO Certification of Natural ID Fingerprint Solutions 2Synaptics Announces FIDO Certification of Natural ID Fingerprint Solutions 3
... it, bread that contains critical nutrients could help combat ... of a group of Johns Hopkins University undergraduate students ... so that it yields beta carotene, the orange substance ... turns into vitamin A. The students, project ...
... likely, you would be disgusted if confronted with a ... worms. Or a particularly bloody wound. Or a horribly ... disgust you feel may lend important insight into your ... scientists closely measured people,s physiological reactions as they looked ...
... -- Low levels of a brain protein that regulates gene ... disorder, a complex and sometimes disabling psychiatric disease. As reported ... journal of The International Society for Bipolar Disorders, levels of ... of the brain in postmortem samples from patients with bipolar ...
Cached Biology News:Students coax yeast cells to add vitamins to bread 2Students coax yeast cells to add vitamins to bread 3Students coax yeast cells to add vitamins to bread 4That's gross!: Study uncovers physiological nature of disgust in politics 2Gene regulatory protein is reduced in bipolar disorder 2Gene regulatory protein is reduced in bipolar disorder 3
... Complete kit for stabilizing 1.5mg of purified ... optimised for the stabilization of aqueous RNA ... methods such as guanidine, phenol/chloroform, silica, oligo ... StabMRT Kits contain all the necessary components ...
... stabilizing 50g of purified RNA samples for RT-PCR ... all of the advantages and applications you expect ... RNA can be used for enzymatic applications such ... been optimised for the stabilization of aqueous RNA ...
Blasticidin resistance gene (bsr), provided in a pORF plasmid. pORF is an expression plasmid selectable with Ampicillin....
Puromycin resistance gene (pac), provided in a pORF plasmid. pORF is an expression plasmid selectable with Ampicillin....
Biology Products: